has granted Fast Track Designation for topically applied ATR-04 to treat moderate to severe Epidermal Growth Factor Receptor inhibitor (EGFRi) associated dermal toxicity. BRANFORD, Conn., ...

At close: November 18 at 4:00 PM EST ...